What are the current guidelines for restarting antiplatelet therapy after an intracerebral hemorrhage?

Restarting Antiplatelet Therapy After Intracerebral Hemorrhage

For patients with spontaneous ICH who had a prior indication for antiplatelet therapy, resumption of antiplatelet monotherapy beyond 24 hours after ICH onset is reasonable and appears safe, with current evidence suggesting it does not increase recurrent ICH risk and may reduce major adverse cardiovascular events.

Current Guideline Consensus (2023)

Multiple international guidelines now provide Level B evidence supporting antiplatelet resumption after ICH 1:

• United States (AHA/ASA 2022): Resumption of antiplatelet therapy may be reasonable for prevention of thromboembolic events based on benefit-risk consideration 2
• Canada: Resuming antiplatelet therapy is reasonable in patients with continued indication 1
• China: Antiplatelet monotherapy may be considered; aspirin can be restored within a few days, though optimal timing remains unclear 1
• UK/Ireland: Restarting antiplatelet treatment beyond 24 hours after ICH symptom onset may be considered 1

Evidence-Based Decision Algorithm

The 2023 Stroke guidelines provide a structured approach 1:

Scenario 1: ICH Associated with Prior Antithrombotic Use + History of MACE + No Atrial Fibrillation

• Action: Start antiplatelet agent(s) - this represents a strong indication
• Rationale: Prior use indicates established cardiovascular risk that likely exceeds recurrent ICH risk

Scenario 2: ICH NOT Associated with Antithrombotic Use + History of MACE + No Atrial Fibrillation

• Action: Avoid antiplatelet agents - strong indication to avoid
• Rationale: Lack of prior use suggests lower thrombotic risk or higher bleeding susceptibility

Scenario 3: ICH Without MACE or ICH With Atrial Fibrillation

• Action: Case-by-case decision based on estimated net effect
• Consider enrollment in ongoing RCTs (ASPIRING, ENRICH-AF, ASPIRE, PRESTIGE-AF) 1

Key Supporting Evidence

The RESTART trial (2019) fundamentally changed practice by showing counterintuitive results 1:

• 537 ICH survivors associated with antithrombotic use
• Antiplatelet resumption showed lower recurrent ICH risk: 4% vs 9% (adjusted HR 0.51,95% CI 0.25-1.03, p=0.060)
• No significant increase in major hemorrhagic events over 2 years

Recent meta-analysis (2025) strengthens this evidence 3:

• 5,554 patients across 10 studies
• Early antiplatelet therapy reduced recurrent ICH by 46% (RR 0.54,95% CI 0.37-0.78, p=0.001)
• No significant differences in ischemic stroke, major hemorrhagic events, or ischemic vascular outcomes
• All-cause mortality showed trend toward benefit (RR 0.81,95% CI 0.65-1.01, p=0.06)

Timing Considerations

When to restart: Beyond 24 hours after ICH symptom onset 1

A 2023 real-world study comparing early (≤30 days) vs late (31-365 days) resumption found 4:

• Similar 1-year recurrent ICH risk (3.12% vs 3.27%)
• Early resumption was as safe as delayed resumption
• Patients without prior cerebrovascular disease had lower mortality and major hemorrhagic events with early resumption
• Patients with chronic kidney disease had lower ischemic stroke risk with early resumption

Critical Clinical Caveats

Risk stratification is essential 1:

• Assess baseline risk of recurrent ICH (consider: lobar location, cerebral amyloid angiopathy, prior ICH, uncontrolled hypertension)
• Weigh against risk of occlusive vascular events (consider: prior MI, coronary stents, peripheral vascular disease, prior ischemic stroke)

Common pitfalls to avoid:

• Do not automatically restart antiplatelets without assessing individual thrombotic vs hemorrhagic risk
• Avoid dual antiplatelet therapy unless absolutely necessary (e.g., recent coronary stent) - associated with 43% higher early mortality 5
• Do not delay decision-making indefinitely; evidence supports decisions within days to weeks

Preferred agent: Aspirin monotherapy is most studied 1. The optimal choice between different antiplatelet agents remains uncertain 1.

Current Practice Reality

Despite guideline support, real-world prescription rates remain low 6:

• Only 10.4% of ICH patients discharged on antiplatelet therapy
• Only 16.6% of those on pre-ICH antiplatelet therapy had it restarted
• This represents significant undertreatment given emerging safety data

Strength of Evidence Limitations

All guidelines grade this as Level B evidence because 1:

• RESTART was a pilot-phase RCT with relatively small sample size (537 patients)
• Effect estimates remain imprecise
• Optimal timing remains uncertain
• Choice of specific antiplatelet agent unclear
• Most data from UK populations (generalizability concerns)

The definitive ASPIRING trial (target 4,148 patients) is ongoing to provide Level A evidence 1.

Practical Recommendation

For patients with spontaneous ICH who were on antiplatelet therapy pre-ICH for secondary prevention of cardiovascular events (without atrial fibrillation), restart aspirin monotherapy after 24-48 hours once acute hemorrhage is stable, unless there are specific contraindications such as recurrent lobar ICH or major extracranial hemorrhage. This approach balances the high cardiovascular risk against the now-established lower-than-expected recurrent ICH risk 1, 3, 4.